Posts Tagged ‘biomarkers’

Breath test for mesothelioma may be a future diagnostic tool

13 Jun 2017 by Sarah Mahan under Research/Treatment

upper body 944557 960 720 100x100 Breath test for mesothelioma may be a future diagnostic toolBreathalyzers are a staple for testing the sobriety of swerving drivers on the road, and now researchers in Belgium are trying to make a similar breath test a staple in mesothelioma treatment. (more…)


SMRP biomarker can indicate pleural mesothelioma patient outcomes

22 May 2017 by Sarah Mahan under Research/Treatment

587px Researcher looks through microscope 11 100x100 SMRP biomarker can indicate pleural mesothelioma patient outcomesWhen biomarkers occur at elevated levels in the blood, they typically indicate disease, and testing for specific biomarkers helps doctors determine from which disease a patient is suffering. New research has shown a biomarker long used to diagnose malignant pleural mesothelioma may be a beneficial way to predict patient outcomes as well. (more…)


Researchers find new technique for DMM identification

18 Apr 2017 by Sarah Mahan under Research/Treatment

587px Researcher looks through microscope 11 100x100 Researchers find new technique for DMM identification Diagnosing diffuse malignant mesothelioma (DMM) typically relies on tumor characteristics like structure and the presence of certain biomarkers. However, DMM is often hard to distinguish from other cancers of the lung and between its three subtypes: epithelioid, sarcomatoid and biphasic. To help ease the confusion, German researchers have developed a new tissue-sample imaging and collecting technique for DMM, according to Mesothelioma Research News. (more…)


Biomarker could help determine between mesothelioma and lung cancer

13 Feb 2017 by Sarah Mahan under Research/Treatment

GHS pictogram silhouette1 100x100 Biomarker could help determine between mesothelioma and lung cancer Sarcomatoid mesothelioma—a subtype of the deadly cancer associated with asbestos exposure—is the rarest form of the cancer and the most resistant to treatment. A new study published in Modern Pathology points to a newly discovered biomarker as a key to differentiating between sarcomatoid mesothelioma and lung sarcomatoid carcinoma, a type of lung cancer mesothelioma is often mistaken as, according to Mesothelioma Research News. (more…)


Researchers find possible test for pleural mesothelioma

8 Dec 2016 by Sarah Mahan under Research/Treatment

research test tubes 100x100 Researchers find possible test for pleural mesotheliomaMesothelioma is a rare cancer associated with asbestos exposure that only affects approximately 3,000 people per year, making it difficult to diagnose as symptoms often overlap with other medical ailments. Having no definitive way to test for the most common form, pleural mesothelioma, which affects the lining of the lungs, makes diagnosing a patient all the more difficult.

But a team of international researchers believes it may have found a way to begin testing for pleural mesothelioma using a specific biomarker, according to Surviving Mesothelioma. (more…)


New mesothelioma drug granted orphan status from EU

26 Jun 2013 by Wendi Lewis under News, Research/Treatment

Verastem banner 100x100 New mesothelioma drug granted orphan status from EUDrug maker Verastem Inc. has obtained approval from the European Commission to proceed with the development of a potential new mesothelioma treatment, which has been granted orphan status. (more…)


Warnex will distribute mesothelioma biomarker test in Canada

12 Aug 2009 by Wendi Lewis under News, Research/Treatment

canadian flag 100x100 Warnex will distribute mesothelioma biomarker test in CanadaIt was announced this week that Warnex Medical Laboratories, a division of Warnex Inc., will be the Canadian distributor for three recently launched genetic biomarker diagnositc tests produced by Rosetta Genomics, Ltd. The tests, branded as miRview™, include a test for the detection and diagnosis of mesothelioma.

Warnex is a life sciences company providing laboratory services to the pharmaceutical and health care industries. The company will market the miRview™ products and will send samples gathered from the tests from Canada to the Rosetta Genomics laboratory in Philadelphia for analysis. Warnex has three facilities, located in Laval and Blainville, Quebec, and Thunder Bay, Ontario.

We’ve written about the miRview™ products on this site in the past. They include miRview™ mets, which can identify the primary tumor site in patients presenting with metastatic cancer; miRview™ squamous, which differentiates squamous from non-squamous, non-small cell lung cancer (NSCLC); and miRview™ meso, which leverages microRNA’s high specificity as biomarkers to differentiate mesothelioma from other carcinomas in the lungs.

All three of the miRview tests utilize MicroRNA technology. According to Rosetta Genomics, microRNAs (or miRNAs) are recently discovered, naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. This is because microRNAs have been shown to have different expression in various pathological conditions, the observation of which can provide a novel diagnostic tool for many diseases.

According to Rosetta Genomics, the miRview™ meso product is a highly accurate test that can help physicians to more easily identify mesothelioma, which can be hard to differentiate from other cancers. The test also can help rule out a meso diagnosis in patients who have been diagnosed with adenocarcinoma of the lung and who also have been exposed to asbestos, which is known to cause mesothelioma.